semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Coronary Heart Disease the presence of an established diagnosis in patients with coronary artery disease unstable angina pectoris (NS). When making a diagnosis, the recommendations of ESH / ESC (2015) and RCO / WHO (2014) were used stable exertional angina (SSN) I-III FC. When making the diagnosis, the IHD classification was used, adopted at the IV Congress of Cardiologists of the Republic of Uzbekistan (2000), as well as in accordance with the recommendations of ESH / ESC (2019) and RCO / WHO (2017)  The patient's refusal to participate in the study Pregnancy and lactation Severe and unstable condition of the patient, making it difficult to conduct a questionnaire (for ethical reasons) Acute violation of cerebral circulation History of acute or chronic psychosis The presence of concomitant acute diseases or chronic diseases in the acute stage. Throughout the study, all patients were assigned the right to voluntarily withdraw from the study at their own request, notifying the researcher in writing or orally
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Refractive Errors Understand and sign an Informed Consent that has been approved by an Institutional Review Board Successful wear of spherical weekly/monthly soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months Willing to stop wearing habitual contact lenses for the duration of study participation Other protocol-defined may apply  Any condition that contraindicates contact lens wear, as determined by the Investigator Any use of systemic or ocular medications that contraindicates contact lens wear, as determined by the Investigator History of refractive surgery or plan to have refractive surgery during the study Current or history of dry eye in either eye that, in the opinion of the Investigator, would preclude contact lens wear Habitual contact lenses worn in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment Any use of topical ocular medications or artificial tear or rewetting drops that would require instillation during contact lens wear Monovision or multifocal contact lens wear Other protocol-defined
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Inflammatory Rheumatism Inflammatory rheumatic disease  Inability to complete the testing procedures Pregancy Not able to perform exercise intervention Planed surgeries or other plans during initial exercise intervention period than directly will effect the testing or training Access to a smartphone Less than 80% compliance of planned training sessions
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Covid19 Consultants and specialists of all general and special surgical specialties and subspecialties in Jordan  None
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Patellofemoral Pain Syndrome Patellar Instability Subject is aged ≥18 years old Subject has patellofemoral syndrome The current condition of his/her knee allows the subject to keep a regular physical activity Subject has been informed and is willing to sign an informed consent form Subject is willing to comply with protocol requirements and return to the study center for all clinical evaluations and required follow-up (18 weeks) Subject is affiliated to the French social security regime Non-Inclusion Subject has conditions that may interfere with his/her ability to understand protocol requirements, participate in scheduled visits, or provide his/her informed consent Subject has worn a support (knee brace or articulated orthosis) in the last month during his/her sport practice Subject has any medical condition that could impact the study at investigator's discretion Subject has a known hypersensitivity or allergy to the components of the device (polyamide, cotton, elastane, elastodiene, polyester)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  COVID-19 Infection Parathyroid Gland Parathyroid Hormone Calcium Phosphorus Alkaline Phosphatase To accept research Being over the age of 18 COVID 19 test results to be positive Not taking parathyroid disease medication before Receiving inpatient treatment in the COVID service in the hospital  Not accepting research Be under the age of 18 Negative COVID 19 test results for patients COVID patients treated as outpatient Parathyroid disease in the healthy control group
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 15.0-49.0,  Contraceptive Behavior females used or currently using long-term contraception  never users of contraception
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Musculoskeletal Pain Chronic Pain Joint Pain Stiffness of Unspecified Joint, Not Elsewhere Classified acute or chronic musculoskeletal pain scoring above 4 in the Visual Analogue Scale (VAS) diagnostic of either tendinopathy, vertebral algias, sprains or symptomatic osteoarthritis  diagnostic in either neuropathic chronic pain, fibromyalgia or neoplasia allergy to any ingredient in the formula
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  X-linked Hypophosphatemia Male or female, aged ≥ 18 years, inclusive Diagnosis of X-linked Hypophosphatemia supported by classic clinical features of adult XLH (e.g. short statue or bowed legs, clinical symptoms as judged by the investigator) and at least one of the following at Screening visit documented PHEX mutation in either the patient, or in a directly related family member with appropriate X-linked inheritance Increased serum levels of c-term FGF23 or iFGF23 Biochemical findings consistent with XLH at Screening visit following overnight fasting Serum phosphorus level or TmP/GFR below lab specific lower limit of normal (LLN) Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min (using the Chronic Kidney Disease Epidemiology Collaboration equitation) or eGFR of 30 up to 60 mL/min at Screening visit with confirmation that the renal insufficiency is not due to nephrocalcinosis Subjects who provide written informed consent after the nature of the study has been explained, and prior to any research-related procedures  Hypocalcemia or hypercalcemia, defined as serum calcium levels outside the age-adjusted normal limits and deemed as clinically significant in the opinion of the investigator Vitamin D deficiency (25OH D3 < 20ng/ml); if Vitamin D is low at screening, substitution is allowed and recompensation has to be confirmed before treatment start by normalized levels of Vitamin D (25OH D3 ≥ 20ng/ml) Serum intact parathyroid hormone (iPTH) >2.5-fold the upper limit of normal (ULN) Severe renal insufficiency with a Glomerular filtration rate (eGFR) <30 at screening Treatment with oral phosphate and / or active vitamin D analogues in addition to Burosumab treatment. (In order to ensure appropriate patient care and preclude any harm due to deficient supply, required supplementation with oral phosphate salts and/or active vitamin D analogues at screening can be continued during the run-in phase but has to be stopped before Baseline and Initiation of treatment with Burosumab.) Treatment with bisphosphates or Denosumab within the last 6 months Treatment with Teriparatide within the last 3 months Intake of calcimimetics within 30 days before screening Patients with known hypersensitivity to Burosumab and the active substances of any of the excipients of Burosumab Presence of a concurrent disease or condition that would interfere with study participation or affect safety in the opinion of the investigator
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain Radiculopathy Lumbar Sciatica non-specific low back pain, spinal stenosis, radiculopathy moderate disability or worse (20-100 points on Oswestry Disability Index)  co-morbidity making the patients unable to move unsufficient Danish-skills patients who already monitored their activity by watch or phone on a daily basis allergy to band-aid pregnancy or breast-feeding patients referred for back-surgical evaluation
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-41.0,  Habitual Abortion Recurrent Pregnancy Loss Fertility Disorders Miscarriage Women with ≥ 2 consecutive pregnancy losses (miscarriages or biochemical pregnancies) ≤ completed gestational week 10 after ART with the present partner or with an egg/semen donor  BMI ≥35 2. Age ≥41 3. Significant uterine malformation(s) 4. Known parental balanced chromosomal translocations 5. ≥2 previous pregnancies with fetuses with known abnormal karyotype 6. Patients with IgA deficiency, IgA-autoantibodies or hyperprolinaemia 7. Treatment with medication interacting with prednisolone CYP3A4-inhibitors (fx erythromycin, itraconazole, ritonavir, lopinavir), CYP3A4-inductors (fx phenobarbital, phenytoin og rifampicin), loop diuretics, thiazides, amphotericin B, beta2-agonists, antidiabetics, interleukin-2, somatotropins, anticholinergics and regular treatment with NSAIDs. 8. Patients with moderate/severe hypertension, diabetes mellitus, heart insufficiency, severe mental disorders, Cushing syndrome, myasthenia gravis, ocular herpes simplex, pheochromocytoma, systemic sclerosis, and moderate/severe renal dysfunction. 9. Patients with a clinical or biochemical profile indicating need for heparin or levothyroxine treatment during pregnancy 10. Previous treatment with IVIg 11. Allergy to prednisolone and/or IVIg 12. AMH <4 pmol/L. If transfer of donor egg is planned for her IVF cycle, the AMH value will not be an criterion
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Chronic Kidney Disease to 79 years of age, inclusive Chronic Kidney Disease Stage 3 (Estimated Glomerular Filtration Rate [eGFR] 30 to 59 milliliters [mL]/minute) or Stage 4 participants (eGFR of <30 mL/minute that were not yet on dialysis). eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) Hemoglobin (Hgb) <13.5 grams per deciliter (g/dL) except for Polycystic Kidney Disease (PKD) participants, in which hemoglobin was to be ≤14 g/dL Transferrin saturation (TSAT) >12% and complete blood count (CBC) indicating normocytic red blood cell morphology, unless the medical monitor and investigator agreed that the subject was appropriate for this study Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤1.8 x upper limit of normal (ULN) Alkaline phosphatase ≤2 x ULN Bilirubin ≤1.5 x ULN Female participants were not pregnant or breast-feeding. Women of childbearing potential agreed to use an acceptable method of contraception Non-vasectomized male participants agreed to use an acceptable method of contraception Understood the procedures and requirements of the study and provided written informed consent and authorization for protected health information disclosure  Any medical or psychological condition that in the opinion of the Investigator would have interfered with the participant's ability to provide informed consent or comply with study instructions Any clinically significant or uncontrolled medical condition that in the opinion of the Investigator would have placed the participant at undo risk or would have compromised the interpretability of the findings in this study A body mass index (BMI) of greater than 40 Seropositive for human immunodeficiency virus (HIV) or Hepatitis B surface antigen Seropositive for Hepatitis C virus (HCV) antibodies unless ALT, AST, bilirubin tests were within normal limits History of chronic liver disease Uncontrolled hypertension (diastolic blood pressure [BP] > 110 millimeters of mercury [mm Hg] or systolic BP >190 mm Hg at screening) New York Heart Association Class III or IV congestive heart failure Myocardial infarction, acute coronary syndrome, or stroke within 6 months of dosing History of myelodysplastic syndrome
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Covid19 SLE patients previously diagnosed Patients are not suffering from malignancies Patients have no organ failure nor uncontrolled medical illness Recent COVID-19 infection  Pregnant, lactating females Concurrent malignancies Patients with other autoimmune disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-25.0,  Sports Physical Therapy Male and female clients Players whose age lies between 18 and 25 years Players who played badminton for at least 6 months  Musculoskeletal or neurological disease Pathological condition of spine , hip, knee and pelvic
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pain, Joint Pain, Procedural Meniscectomy Age ≥ 18 Scheduled for arthroscopic meniscectomy or meniscus repair  Multiple-ligament injury Primary ACL reconstruction or ACL revision reconstruction Articular cartilage restoration surgery Evidence of microfracture History of allergy to local anesthetics Pre-existing saphenous neuropathy Unable to be prescribed opioids due to allergy or other reason
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Knee Osteoarthritis Patients with significant knee pain (pain score≥40mm on the 100mmVAS scale); 2. Male or female patients, between 50-75 years old; 3. MRI suggests bone marrow edema-like lesions; 4. Knee osteoarthritis (in accordance with the diagnostic of American College of Rheumatology (ACR) and Chinese Orthopaedic Association); 5. Kellgren-Lawrence gradingⅠorⅡin X-ray  Other forms of active arthritis (such as rheumatoid arthritis or other inflammatory arthritis); 2. Taken non-steroidal anti-inflammatory drugs and central analgesics (such as opioids) within two weeks； 3. Liver function ALT or AST is 1.5 times the upper limit of normal； creatinine clearance <35ml/min； 4. Pregnancy or suckling; 5. Serious heart disease, endocrine, digestive, mental, nervous system diseases or cancer; 6. Active ulcers and a history of upper gastrointestinal bleeding; 7. Esophageal motility disorders, such as esophageal tardiness or stenosis; 8. Renal dysfunction or osteomalacia; 9. Tobacco addiction (mean 10 cigarettes per day or more) or/and alcohol addiction (mean 50ml per day or more); 10. Fresh fracture in the last six months; 11. Serious illnesses and life expectancy<2 years; 12. Allergic to study drugs; 13. Used any study drug or device within 30 days before randomization or within the drug half-life (whichever is longer); 14. Failure to take medication as required; 15. Replacement surgery in the near future; 16. Contraindications to MRI scans (e.g. implanted pacemakers, metal sutures, shrapnel or iron filings in the eyes, claustrophobia, knees too large to use coils); 17. Sensitive to or unsuitable for X-ray exposure (e.g. aplastic anemia, etc); 18. Poor dental health or dental surgery in the near future
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Pain Chronic Instability of Ankle Joint Subject is aged ≥18 years old Subject has chronic pain AND / OR chronic ankle instability The current condition of his/her ankle allows the subject to pursue a usual physical activity Subject has been informed and is willing to sign an informed consent form Subject is willing to comply with protocol requirements and return to the study center for all clinical evaluations and required follow-up (6 weeks) Subject is affiliated to the French social security regime Non-inclusion Subject has conditions that may interfere with his/her ability to understand protocol requirements, participate in scheduled visits, or provide his/her informed consent Subject has worn a support (ankle brace or articulated orthosis) during sports sessions during the last month Subject has any medical condition that could impact the study at investigator's discretion Subject has a known hypersensitivity or allergy to the components of the device (polyamide, elastodiene, elastane, polyester, synthetic rubber)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain Having non-specific chronic low back pain Non-specific chronic low back pain ⩾three months Being over the age of 18 Score of ⩾4 on the Roland-Morris Disability Questionnaire (RMQ) Agree to voluntarily participate in the research  Presence of lumbar stenosis Presence of clinical signs or symptoms of radiculopathy Diagnosis of spondylolisthesis Diagnosis of fibromyalgia Treatment with corticosteroids or other drugs in the previous two weeks History of spinal surgery Presence of central or peripheral system pathology (i.e. stroke, peripheral nerve etc.) Have received a physiotherapy treatment for low back pain before 6 months